Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Blood (2021) 138 (23): 2441–2445.

https://doi.org/10.1182/blood.2021012781

Published: 2021

Includes: Supplemental data

Journal Articles

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Blood (2016) 127 (3): 360–362.

https://doi.org/10.1182/blood-2015-08-662130

Published: 2016

Includes: Supplemental data

Journal Articles

Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience

Jaroslaw Dybko, Olga Haus, MD, Bozena Jazwiec, Tomasz Lonc, Mateusz Sawicki, Kazimierz Kuliczkowski

Blood (2015) 126 (23): 5163.

https://doi.org/10.1182/blood.V126.23.5163.5163

Published: 2015

Journal Articles

Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency

Victor Bengt Pastor Loyola, MSc, Shinsuke Hirabayashi, MD, Sandra Pohl, PhD, Emilia J Kozyra, MSc, Albert Catala, MD, Barbara De Moerloose, MD PhD, Michael Dworzak, MD, Henrik Hasle, MD, Riccardo Masetti, MD, Markus Schmugge, MD, Owen Smith, Jan Starý, MD, Marek Ussowicz, MD, Marry M. van den Heuvel-Eibrink, MD PhD, Ester Mejstrikova, MD PhD, Ulrich Salzer, MD, Michael Lübbert, MD, Daniel Heudobler, MD, David Betts, MD, Jose Cervera, MD, Gudrun Göhring, MD, Oskar A. Haas, Olga Haus, MD, Kyra Michalova, PhD DSc, Francesco Pasquali, MD, Joelle Tchinda, MD, Nadine van Roy, MD, Brigitte Schlegelberger, MD Prof., H. Berna Beverloo, PhD, Peter Noellke, MSc, Ayami Yoshimi, MD, Franco Locatelli, Prof, MD PhD, Brigitte Strahm, MD, Jaroslaw P. Maciejewski, MD PhD, Michael Rehli, PhD, Charlotte M Niemeyer, Prof, MD, Marcin W Wlodarski, MD

Blood (2015) 126 (23): 299.

https://doi.org/10.1182/blood.V126.23.299.299

Published: 2015

Journal Articles

The Hasford Score Correlates with the Long-Term Molecular Response to Imatinib Treatment for Chronic Myeloid Leukemia Patients and May be Useful for Differentiating Low and Intermediate Risk Patients: A Single Institution Experience

Jaroslaw Dybko, MD PhD, Ewa Medras, MD, Olga Haus, MD PhD, Bozena Jazwiec, MSC, Tomasz Wrobel, MDPhD, Kazimierz Kuliczkowski, MD PhD Prof.

Blood (2014) 124 (21): 3152.

https://doi.org/10.1182/blood.V124.21.3152.3152

Published: 2014

Journal Articles

Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia – Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2014) 124 (21): 2347.

https://doi.org/10.1182/blood.V124.21.2347.2347

Published: 2014

Journal Articles

CD117 (c-kit) Expression On CD34+ Cells Participates In The Cytogenetic Response To Imatinib In CML Patients In First Chronic Phase

Jaroslaw Dybko, MD PhD, Ewa Medras, MD, Olga Haus, MD, PhD, Prof., Bozena Jazwiec, MSC, Joanna Urbaniak, PhD, Mieczyslaw Wozniak, PhD Prof., Kazimierz Kuliczkowski, Professor

Blood (2013) 122 (21): 3990.

https://doi.org/10.1182/blood.V122.21.3990.3990

Published: 2013

Journal Articles

Comparable Toxicity and Outcome of Acute Myeloid Leukemia (AML) Fit Patients Therapy Independently If Daunorubicin or Idarubicin Were Added to Cytarabine/Cladribine Induction Regimens – the Single Centre Study

Sebastian Grosicki, MD, PhD, Marek Kriegler, Ewa Bodzenta, Maja Twardosz, Ilona Szypula, Marcin Fejklowicz, Olga Haus, MD, PhD, Teresa Kurzawa, Agnieszka Barchnicka

Blood (2012) 120 (21): 4337.

https://doi.org/10.1182/blood.V120.21.4337.4337

Published: 2012

Journal Articles

Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? – Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,

Blood (2011) 118 (21): 3537.

https://doi.org/10.1182/blood.V118.21.3537.3537

Published: 2011

Journal Articles

Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.

Blood (2009) 114 (22): 2055.

https://doi.org/10.1182/blood.V114.22.2055.2055

Published: 2009

Journal Articles

Gene Expression and Ex Vivo Drug Sensitivity Profiles in Children with Acute Leukemia: An Insight for High-Dose Therapy and Role of Etoposide and Fludarabine.

Joanna Szczepanek, Michal Jarzab, Malgorzata Oczko-Wojciechowska, Malgorzata Kowalska, Andrzej Tretyn, Olga Haus, Monika Pogorzala, Mariusz Wysocki, Barbara Jarzab, Jan Styczynski

Blood (2009) 114 (22): 2747.

https://doi.org/10.1182/blood.V114.22.2747.2747

Published: 2009

Journal Articles

Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients

Blood (2008) 112 (11): 133.

https://doi.org/10.1182/blood.V112.11.133.133

Published: 2008

Journal Articles

Incidence and Spectrum of MLL Gene Rearrangements in Pediatric Acute Leukemias in Poland

Blood (2008) 112 (11): 4851.

https://doi.org/10.1182/blood.V112.11.4851.4851

Published: 2008

Journal Articles

Significance of BAALC , MN 1, ERG , CEBP a Gene Expression as New Prognostic Factors, in the Context of Other Molecular Markers in Intermediate Risk AML Group According to Cytogenetics, Including Patients Younger Than 60 Years

Marta Antonina Libura, MD, PhD, Beata Piatkowska-Jakubas, Olga Haus, Izabela Florek, Bozena Jazwiec, PhD, Krystyna Soszynska, PhD, Zoriana Salamanchuk, PhD, Malgorzata Jakobczyk, Szymon Fornagiel, Tomasz Sacha, Marek Kielbinski, Kazimierz Kuliczkowski, Ewa Duszenko, Anna Jaskowiec, Barbara Mucha, Katarzyna Skonieczna, Aleksander Skotnicki

Blood (2008) 112 (11): 4855.

https://doi.org/10.1182/blood.V112.11.4855.4855

Published: 2008

Journal Articles

Clinical Relevance of Multidrug Resistance Proteins Expression in Patients with De Novo Acute Myeloid Leukaemia.

Maria Podolak-Dawidziak, Danuta Dus, Marek Kielbinski, Maria Paprocka, Olga Haus, Malgorzata Kuliszkiewicz-Janus, Kazimierz Kuliczkowski

Blood (2006) 108 (11): 4363.

https://doi.org/10.1182/blood.V108.11.4363.4363

Published: 2006

Journal Articles

High Incidence of Ancestral HLA Haplotype 8.1 and Incomplete DH-JH Immunoglobulin Rearrangement in Persistent Polyclonal B-Cell Lymphocytosis.

Dariusz Wolowiec, MD, PhD, Miroslaw Majewski, MD, Jacek Nowak, MD, PhD, Beata Stella-Holowiecka, MD, PhD, Angelika Krawcewicz, MD, Renata Mika-Witkowska, Hanna Makuch-Lasica, Iwona Solarska, Olga Haus, MD, PhD, Ewa Duszenko, Kazimierz Kuliczkowski, MD, PhD, Krzysztof Warzocha, MD, PhD

Blood (2005) 106 (11): 3923.

https://doi.org/10.1182/blood.V106.11.3923.3923

Published: 2005

Journal Articles

Independent Prognostic Significance of Cytogenetics, Immunophenotype, Tumor Burden, and Age in Acute Myeloid Leukemia. Analysis of Patients Treated within PALG 1999 Prospective, Randomized Study.

Sebastian Grosicki, MD, Jerzy Holowiecki, Sebastian Giebel, MD, Olga Haus, MD, Beata Stella-Holowiecka, MD, Krystyna Jagoda, Aleksandra Bartkowska-Chrobok

Blood (2004) 104 (11): 4395.

https://doi.org/10.1182/blood.V104.11.4395.4395

Published: 2004

NARROW

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience

Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency

The Hasford Score Correlates with the Long-Term Molecular Response to Imatinib Treatment for Chronic Myeloid Leukemia Patients and May be Useful for Differentiating Low and Intermediate Risk Patients: A Single Institution Experience

Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia – Retrospective Analysis of Polish Adult Leukemia Group (PALG)

CD117 (c-kit) Expression On CD34+ Cells Participates In The Cytogenetic Response To Imatinib In CML Patients In First Chronic Phase

Comparable Toxicity and Outcome of Acute Myeloid Leukemia (AML) Fit Patients Therapy Independently If Daunorubicin or Idarubicin Were Added to Cytarabine/Cladribine Induction Regimens – the Single Centre Study

Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? – Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,

Gene Expression and Ex Vivo Drug Sensitivity Profiles in Children with Acute Leukemia: An Insight for High-Dose Therapy and Role of Etoposide and Fludarabine.

Incidence and Spectrum of MLL Gene Rearrangements in Pediatric Acute Leukemias in Poland

Significance of BAALC , MN 1, ERG , CEBP a Gene Expression as New Prognostic Factors, in the Context of Other Molecular Markers in Intermediate Risk AML Group According to Cytogenetics, Including Patients Younger Than 60 Years

Clinical Relevance of Multidrug Resistance Proteins Expression in Patients with De Novo Acute Myeloid Leukaemia.

High Incidence of Ancestral HLA Haplotype 8.1 and Incomplete DH-JH Immunoglobulin Rearrangement in Persistent Polyclonal B-Cell Lymphocytosis.

Independent Prognostic Significance of Cytogenetics, Immunophenotype, Tumor Burden, and Age in Acute Myeloid Leukemia. Analysis of Patients Treated within PALG 1999 Prospective, Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only